SynthesisMolecular biology reports2012
Differential effects of paraoxonase 1 (PON1) polymorphisms on cancer risk: evidence from 25 published studies.
Synthesis in Molecular biology reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Association of PON1, LEP and LEPR Polymorphisms with Susceptibility to Breast Cancer: A Meta-Analysis.Asian Pacific journal of cancer prevention : APJCP · 2021Pooled it
- Comparative cytotoxicity and genotoxicity of commercial glyphosate-based herbicide formulations and co-formulants in human leukocyte and hepatocyte cell lines.Frontiers in toxicology · 2026Article
- Causal relationship between blood metal levels and breast cancer risk: a Mendelian randomization study in East Asian populations.Discover oncology · 2025Article
- Serum Paraoxonase-1 Activity and the Risk of Prostate Cancer Recurrence in Patients Treated with Radiotherapy.Antioxidants (Basel, Switzerland) · 2022Article
- Association of Paraoxonase 1 Gene Polymorphisms with the Risk of Breast Fibroadenoma and Breast Cancer in the Females of Guangxi, China.Journal of healthcare engineering · 2022Article
- Association betweenOncotarget · 2017Article
- Identification of novel potential genetic predictors of urothelial bladder carcinoma susceptibility in Pakistani population.Familial cancer · 2017Article
- A pilot study assessing the association between paraoxonase 1 gene polymorphism and prostate cancer.Turkish journal of urology · 2017Article
- Paraoxonase-1 (PON1) induces metastatic potential and apoptosis escape via its antioxidative function in lung cancer cells.Oncotarget · 2017Article
- Phenotype distribution of the paraoxonase gene in patients with cardiac disease.Archives of medical science : AMS · 2017Article
- Paraoxonase 1 gene polymorphisms are associated with an increased risk of breast cancer in a population of Chinese women.Oncotarget · 2017Article
- Article
- Article
- Effect of PON1 gene polymorphisms in Turkish patients with hepatocellular carcinoma.Meta gene · 2013Article
- Pharmacogenetics of paraoxonase activity: elucidating the role of high-density lipoprotein in disease.Pharmacogenomics · 2013Review
- MMP-2 -1306C>T polymorphism in breast cancer: a case-control study in a South European population.Molecular biology reports · 2013Article
- Paraoxonase-1 status in patients with hereditary hemochromatosis.Journal of lipid research · 2013Article
- HSP90, HSPA8, HIF-1 alpha and HSP70-2 polymorphisms in breast cancer: a case-control study.Molecular biology reports · 2012Article
- HTERT MNS16A polymorphism in breast cancer: a case-control study.Molecular biology reports · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Paraoxonase is an HDL-associated enzyme that plays a preventive role against oxidative stress, which is thought to contribute to cancer development. PON1 activity varies widely among individuals, which is in part related to two common nonsynonymous polymorphisms in the PON1 gene (Q192R and L55M). The polymorphisms in PON1 have been implicated in cancer risk. However, results from the studies to date have been conflicting. To clarify the association, a meta-analysis was performed for 7,073 cases and 9,520 controls from 25 published case-control studies. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of the association. Significant associations between PON1-L55M but not Q192R polymorphism and total cancer were observed from all the comparisons. In stratified analyses, PON1-55M allele was a risk factor for breast cancer. Similarly, increased risk was observed for prostate cancer (OR = 1.18, 95% CI: 1.01-1.36, P (heterogeneity) = 0.260) and Caucasian population (OR = 1.18, 95% CI: 1.02-1.38, P (heterogeneity) = 0.1) of the LM genotype, compared with the LL genotype. For PON1-Q192R polymorphism, PON1-192R allele was a decreased risk factor for cancer in the Asian group (RR vs QQ: OR = 0.61, 95% CI: 0.38-0.98, P (heterogeneity) = 0.268; QR vs QQ: OR = 0.71, 95% CI: 0.52-0.96, P (heterogeneity) = 0.130; RR + QR vs QQ: OR = 0.71, 95% CI: 0.53-0.95, P (heterogeneity) = 0.135). Although some modest bias could not be eliminated, this meta-analysis suggests that the PON1-55M allele is a risk factor for the development of cancer, in particular for breast cancer. Future studies with larger sample sizes are warranted to further evaluate these associations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.